Briquilimab

Phase 2Active

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Urticaria Chronic

Conditions

Urticaria Chronic

Trial Timeline

Nov 26, 2024 → Sep 30, 2026

NCT ID

NCT06736262

About Briquilimab

Briquilimab is a phase 2 stage product being developed by Jasper Therapeutics for Urticaria Chronic. The current trial status is active. This product is registered under clinical trial identifier NCT06736262. Target conditions include Urticaria Chronic.

What happened to similar drugs?

1 of 20 similar drugs in Urticaria Chronic were approved

Approved (1) Terminated (2) Active (17)

🔄CT-P39 + EU-approved XolairCelltrionPhase 3

🔄LOU064NovartisPhase 3

🔄Ligelizumab + OmalizumabNovartisPhase 3

🔄LOU064 (blinded) + placeboNovartisPhase 3

🔄Remibrutinib + Remibrutinib matching placebo + Dupilumab + Placebo solution for injectionNovartisPhase 3

🔄omalizumab + omalizumabNovartisPhase 3

🔄RemibrutinibNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06736262	Phase 2	Active	Nov 26, 2024	Sep 30, 2026	Urticaria Chronic
NCT06592768	Phase 1	Terminated	Nov 26, 2024	Aug 11, 2025	Allergic Asthma
NCT06353971	Phase 1/2	Terminated	Mar 18, 2024	Jul 31, 2025	Chronic Inducible Urticaria
NCT06162728	Phase 1/2	Active	Nov 29, 2023	Oct 31, 2026	Chronic Spontaneous Urticaria

Competing Products

20 competing products in Urticaria Chronic

See all competitors

Product	Company	Stage	Hype Score
KPL-716 + Placebo	Kiniksa Pharmaceuticals	Phase 2	29
THB001	Third Harmonic Bio	Phase 1	11
Briquilimab	Jasper Therapeutics	Phase 1/2	26
Briquilimab	Jasper Therapeutics	Phase 1/2	14
CT-P39 + EU-approved Xolair	Celltrion	Phase 3	40
Omalizumab	Celltrion	Pre-clinical	33
LY3454738 + Placebo	Eli Lilly	Phase 2	27
AZD1981 + Placebo	AstraZeneca	Phase 2	35
Benralizumab + Placebo and Benralizumab	AstraZeneca	Phase 2	27
LOU064	Novartis	Phase 3	40
Ligelizumab + Omalizumab	Novartis	Phase 3	40
Ligelizumab + Placebo	Novartis	Phase 1	21
Omalizumab	Novartis	Phase 2	35
canakinumab	Novartis	Phase 2	35
LOU064	Novartis	Phase 2	35
Omalizumab (Xolair) + Placebo	Novartis	Phase 2/3	38
LOU064 Arm 1 + LOU064 Arm 2 + LOU064 Arm 3 + LOU064 Arm 4 + LOU064 Arm 5 + LOU064 Arm 6 + Placebo arm	Novartis	Phase 2	35
LOU064 (blinded) + placebo	Novartis	Phase 3	47
Remibrutinib + Remibrutinib matching placebo + Dupilumab + Placebo solution for injection	Novartis	Phase 3	47
omalizumab + omalizumab	Novartis	Phase 3	40